Trial Profile
A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of GSK2330672 Administration in Patients With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs Linerixibat (Primary) ; Ursodeoxycholic acid
- Indications Primary biliary cirrhosis; Pruritus
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
- 09 Feb 2017 Results of final analysis published in The Lancet.
- 04 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.